Dose Finding Study in COPD

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.

Official Title
-----------------
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: BEA 2180 BR
* Drug: tiotropium


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 >=30% and <= 60% of predicted normal and FEV1 <=70% of FVC at the baseline PFTs at Visit 1 (at both timepoints). All patients must have an increase in FEV1 of at least 12% from baseline (th e -10 minute measurement) 45 min after inhalation of 80 ?g Atrovent MDI. Male or female patients 40 years of age or older. Smoker or ex-smoker with a history of more than 10 pack years. 1. Patients with any other significant disease will be excluded. 2. Patients with a history of asthma or allergic rhinitis will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 83 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: BEA 2180 BR|nan|
|Drug: tiotropium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trough forced expiratory volume (FEV1) response after four weeks of treatment. |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trough FEV1 response after 1 and 2 weeks |  | after 1 and 2 weeks | 
| Trough FVC response after 1, 2 and 4 weeks |  | after 1, 2 and 4 weeks | 
| FEV1, FVC AUC0-6h and peak response after 0, 1, 2 and 4 weeks |  | after 0, 1, 2 and 4 weeks | 
| Individual FEV1 and FVC measurements at each time point |  | 4 weeks | 
| Weekly mean pre-dose morning and evening PEFR |  | 4 weeks | 
| Weekly mean number of occasions of rescue therapy used per day [as occasion requires (PRN) albuterol] |  | 4 weeks | 
| COPD symptom scores (wheezing, shortness of breath, coughing and tightness of chest) |  | 4 weeks | 
| Physician's Global Evaluation |  | 4 weeks | 
| All adverse events |  | 7 weeks | 
| Pulse rate and blood pressure (seated) recorded in conjunction with spirometry up to the three hour pulmonary function test (PFT) |  | 4 weeks | 
| 12-lead ECGs at baseline (-10 minutes) and at 25 minutes, 2 and 6 hours post dose (Visits 2 and 5) |  | 4 weeks | 
| drug plasma concentrations |  | 4 or 7 weeks | 
| drug urine concentrations |  | 4 or 7 weeks |